Sequent Scientific [SEQUENT] vs Piramal Pharma [PPLPHARMA] Detailed Stock Comparison

Sequent Scientific Ltd.

NSE
Loading...

Piramal Pharma Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Sequent Scientific Ltd. wins in 9 metrics, Piramal Pharma Ltd. wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.

View Metrics Details

Vital Metrics Comparison

Metric Sequent Scientific Ltd. Piramal Pharma Ltd. Better
P/E Ratio (TTM) 123.42 269.79 Sequent Scientific Ltd.
Price-to-Book Ratio 6.21 2.47 Piramal Pharma Ltd.
Debt-to-Equity Ratio 55.31 60.08 Sequent Scientific Ltd.
PEG Ratio 0.23 -0.38 Sequent Scientific Ltd.
EV/EBITDA 30.04 25.20 Piramal Pharma Ltd.
Profit Margin (TTM) 2.52% -1.84% Sequent Scientific Ltd.
Operating Margin (TTM) 9.66% -0.80% Sequent Scientific Ltd.
EBITDA Margin (TTM) 9.66% N/A N/A
Return on Equity 6.64% 1.12% Sequent Scientific Ltd.
Return on Assets (TTM) 4.91% 0.58% Sequent Scientific Ltd.
Free Cash Flow (TTM) $442.73M $2.28B Piramal Pharma Ltd.
Dividend Yield N/A 0.07% N/A
1-Year Return 26.71% -18.17% Sequent Scientific Ltd.
Price-to-Sales Ratio (TTM) 5.29 2.25 Piramal Pharma Ltd.
Enterprise Value $55.23B $240.47B Piramal Pharma Ltd.
EV/Revenue Ratio 3.33 2.71 Piramal Pharma Ltd.
Gross Profit Margin (TTM) 54.46% 63.25% Piramal Pharma Ltd.
Revenue per Share (TTM) $66 $67 Piramal Pharma Ltd.
Earnings per Share (Diluted) $1.63 $-1.23 Sequent Scientific Ltd.
Beta (Stock Volatility) 0.96 0.19 Piramal Pharma Ltd.

Sequent Scientific Ltd. vs Piramal Pharma Ltd. Stock Performance Analysis

Loading Price Chart...

SEQUENT
PPLPHARMA

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Sequent Scientific Ltd.0.54%-0.20%11.92%29.09%19.28%20.60%
Piramal Pharma Ltd.2.04%1.12%-4.39%20.53%-2.62%-1.58%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Sequent Scientific Ltd.26.71%229.31%-7.05%107.29%69.54%69.54%
Piramal Pharma Ltd.-18.17%77.37%-2.17%-2.17%-2.17%-2.17%

Performance & Financial Health Analysis: Sequent Scientific Ltd. vs Piramal Pharma Ltd.

MetricSEQUENTPPLPHARMA
Market Information
Market Cap i₹84.41B₹199.68B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i762,0042,496,822
90 Day Avg. Volume i791,5673,143,094
Last Close₹251.30₹167.20
52 Week Range₹166.00 - ₹277.35₹132.30 - ₹220.85
% from 52W High-9.39%-24.29%
All-Time High₹336.50 (Jun 28, 2021)₹307.90 (Nov 04, 2024)
% from All-Time High-25.32%-45.70%
Growth Metrics
Quarterly Revenue Growth0.15%-0.03%
Quarterly Earnings Growth4.65%-0.05%
Financial Health
Profit Margin (TTM) i0.03%-0.02%
Operating Margin (TTM) i0.10%-0.01%
Return on Equity (TTM) i0.07%0.01%
Debt to Equity (MRQ) i55.3160.08
Cash & Liquidity
Book Value per Share (MRQ)₹32.38₹61.03
Cash per Share (MRQ)₹2.84₹5.63
Operating Cash Flow (TTM) i₹1.04B₹2.44B
Levered Free Cash Flow (TTM) i₹-14,897,500₹911.30M
Dividends
Last 12-Month Dividend Yield iN/A0.07%
Last 12-Month Dividend i₹0.00₹0.14

Valuation & Enterprise Metrics Analysis: Sequent Scientific Ltd. vs Piramal Pharma Ltd.

MetricSEQUENT (Mar 28, 2026)PPLPHARMA (Apr 21, 2026)
Price Ratios
P/E Ratio (TTM) i123.42269.79
Forward P/E i39.8467.23
PEG Ratio i0.23-0.38
Price to Sales (TTM) i5.292.25
Price to Book (MRQ) i6.212.47
Market Capitalization
Market Capitalization i₹84.41B₹199.68B
Enterprise Value i₹55.23B₹240.47B
Enterprise Value Metrics
Enterprise to Revenue i3.332.71
Enterprise to EBITDA i30.0425.20
Risk & Other Metrics
Beta i0.960.19
Book Value per Share (MRQ) i₹32.38₹61.03

Financial Statements Comparison: Sequent Scientific Ltd. vs Piramal Pharma Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSEQUENT (2025)PPLPHARMA (2025)
Revenue/Sales i15.47B90.61B
Cost of Goods Sold i8.64B35.72B
COGS % of Revenue i55.9%39.4%
Gross Profit i6.83B54.89B
Gross Margin i44.1%60.6%
Research & Development iN/A971.30M
Operating Income (EBIT) i1.19B6.79B
Operating Margin i7.7%7.5%
EBITDA i1.63B16.89B
EBITDA Margin i10.5%18.6%
Pre-Tax Income i443.06M4.15B
Pre-Tax Income % of Revenue i2.9%4.6%
Income Tax i120.47M3.24B
Income Tax % of Revenue i0.8%3.6%
Net Income (Profit) i322.59M911.30M
Profit Margin i2.1%1.0%

Balance Sheet & Liquidity Metrics

MetricSEQUENT (2025)PPLPHARMA (2025)
Cash & Equivalents i626.60M3.69B
Total Current Assets i8.74B57.97B
Total Current Assets % of Revenue i56.5%64.0%
Total Current Liabilities i5.05B37.66B
Total Current Liabilities % of Revenue i32.6%41.6%
Long-Term Debt i3.00B33.13B
Long-Term Debt % of Revenue i19.4%36.6%
Total Shareholders Equity i7.70B81.25B
Retained Earnings i1.25B10.49B
Retained Earnings % of Revenue i8.1%11.6%
Property, Plant & Equipment i2.84B250.60M

Cash Flow Statement Comparison

MetricSEQUENT (2025)PPLPHARMA (2025)
Operating Cash Flow i360.47M2.44B
Operating Cash Flow % of Revenue i2.3%2.7%
Capital Expenditures i-293.87M-6.59B
Free Cash Flow i442.73M2.28B
FCF Margin i2.9%2.5%
Debt Repayment i-1.88B-10.65B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricSEQUENTPPLPHARMA
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i435.72M1.32B
Float Shares i96.00M608.76M
% Held by Insiders i68.03%54.54%
% Held by Institutions i7.40%20.41%
% Held by Public i24.57%25.05%

Dividend Analysis & Yield Comparison: Sequent Scientific Ltd. vs Piramal Pharma Ltd.

MetricSEQUENTPPLPHARMA
Last 12-Month Dividend i₹0.00₹0.14
Last 12-Month Dividend Yield iN/A0.07%
3-Year Avg Annual Dividend i₹0.00₹0.08
3-Year Avg Dividend Yield iN/A0.07%
3-Year Total Dividends i₹0.00₹0.25
Ex-Dividend DateN/AJul 16, 2025